← Back to Search

Monoclonal Antibodies

Erenumab for Hemicrania Continua

Phase 2
Waitlist Available
Led By Rashmi Halker Singh, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks post erenumab treatment
Awards & highlights

Study Summary

This trial is testing a new drug, erenumab, to see if it can effectively treat hemicrania continua, as well as if it is safe and tolerable for patients.

Eligible Conditions
  • Hemicrania Continua

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks post erenumab treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks post erenumab treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Headache Days
Secondary outcome measures
Headache Freedom
Migraine Days
Remission Rate

Side effects data

From 2023 Phase 4 trial • 701 Patients • NCT04084314
35%
COVID-19
19%
Nasopharyngitis
15%
Constipation
9%
Fatigue
7%
Hypertension
6%
Depression
6%
Back pain
6%
Immunisation reaction
6%
Headache
6%
Migraine
5%
Nausea
5%
Arthralgia
4%
Vertigo
4%
Alopecia
4%
Pain in extremity
3%
Tonsillitis
3%
Cystitis
3%
Urinary tract infection
3%
Oropharyngeal pain
3%
Dizziness
3%
Cough
3%
Chills
3%
Pruritus
3%
Pyrexia
2%
Diarrhoea
2%
Post vaccination fever
2%
Abdominal pain upper
2%
Muscle spasms
2%
Osteoarthritis
2%
Procedural pain
1%
Appendicitis
1%
Intervertebral disc protrusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erenumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment with ErenumabExperimental Treatment1 Intervention
Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erenumab
FDA approved

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,782 Total Patients Enrolled
Rashmi Halker Singh, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential hazards could arise from taking Erenumab?

"Our team at Power rated Erenumab with a 2 due to the Phase 2 trial's lack of efficacy data despite having supportive safety results."

Answered by AI

Has Erenumab been tested in other research studies?

"At this moment, 18 separate clinical studies for Erenumab are in progress with 3 of them being at Phase 3. The main research hub is Rochester, Minnesota though 549 other sites have ongoing trials as well."

Answered by AI

Are there any enrollment opportunities for prospective volunteers in this research project?

"According to clinicaltrials.gov, this medical trial is actively recruiting participants. The experiment was first listed on August 4th 2021 and has since been updated as recently as September 29th 2022."

Answered by AI

Has this kind of clinical trial ever been conducted before?

"Since its initial research in 2019, sponsored by Amgen and involving 456 patients, erenumab has gained Phase 3 drug approval. Today it is being investigated further as part of 18 active studies across 32 nations and 179 cities."

Answered by AI

Is it possible for me to participate in this clinical experiment?

"To be eligible for enrolment in this trial, prospective patients must suffer from headaches and fall within the age range of 18-66. The team is recruiting a cohort of 20 individuals altogether."

Answered by AI

What is the current recruitment rate for participants of this experiment?

"Yes, records on clinicaltrials.gov indicate that this trial is currently enrolling individuals. It was initially published on August 4th 2021 and underwent a recent update on September 29th 2022. 20 participants are wanted for the research at one location."

Answered by AI

Is enrollment open to minors for this experiment?

"The requirements for participating in this trial stipulate that the patient must be between 18 and 66 years of age. Moreover, there are 21 clinical trials targeting minors and 103 geared towards seniors."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Erenumab For Treatment of Hemicrania Continua
Rashmi B. Halker Singh MD 2021. "Erenumab For Treatment of Hemicrania Continua". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04303845.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top